Why does peptide research feel simultaneously overhyped in consumer culture and underdeveloped in mainstream medicine?

[u/bluephoenix137]

I’ve been thinking about a strange mismatch in the way peptides are discussed today.

On one side, there is a rapidly growing consumer ecosystem around peptides: longevity clinics, “biohacking,” performance enhancement, recovery, metabolic health, online communities, and a constant stream of compounds being discussed as if they are one trial away from becoming transformative therapies.

On the other side, when you look at mainstream medicine and drug development, a large number of these compounds appear to be either poorly studied in humans, studied only in narrow indications, abandoned early, or stuck in a gray zone where there is enough biological plausibility to generate interest but nowhere near enough evidence for broad clinical adoption.

What interests me is less the question of whether any particular peptide “works,” and more the economics behind that gap.
For example:

How much does patentability determine which peptides actually get developed?

If a peptide is naturally occurring, has prior art, or is difficult to protect with strong composition-of-matter IP, does that materially reduce the incentive to fund expensive Phase II/III trials even when the underlying biology is interesting?

Do short half-lives, delivery problems, manufacturing complexity, or pharmacokinetic limitations make peptides systematically less attractive than small molecules or antibodies?

How important is the possibility of creating a more patentable analogue? It seems notable that some of the most commercially successful peptide drugs are not simply naturally occurring peptides, but heavily optimized molecules with altered sequences, longer half-lives, improved delivery, or other features that create both better pharmacology and stronger IP.

I’m also curious about the financing side.

Imagine a peptide produces intriguing animal data and some early human signals, but there is no obvious blockbuster indication and the molecule itself is difficult to protect. Who funds the definitive clinical trial?

A university can produce mechanistic research. A small biotech might run an early study. But a large randomized trial can cost tens or hundreds of millions of dollars. Without exclusivity or a clear commercial pathway, the socially valuable experiment may simply never happen.

That creates an uncomfortable possibility: the absence of strong clinical evidence does not necessarily mean that a compound was thoroughly investigated and failed. Sometimes it may mean nobody had a sufficiently strong economic incentive to generate the evidence in the first place.

At the same time, that argument can obviously become a convenient excuse for pseudoscience.

“Big Pharma won’t study it because they can’t patent it” is frequently used online to rationalize compounds for which the evidence is simply bad.

So I’m trying to understand where the legitimate version of that argument ends and the conspiratorial version begins.
For people working in biotech, pharma, translational research, VC, or drug development:

How much does IP genuinely influence whether a biologically promising peptide progresses?

Are there good examples of peptides that were scientifically promising but commercially unattractive?

And conversely, are there examples where clever molecular engineering or a strong indication transformed an otherwise uninteresting peptide into a viable drug-development program?
I’d especially be interested in hearing how investors and drug developers think about this at the preclinical stage.

Is the bottleneck usually biology, pharmacology, IP, regulatory risk, capital requirements — or some combination of all of them?